Taiwan
· Delayed Price · Currency is TWD InnoPharmax Statistics
Total Valuation
InnoPharmax has a market cap or net worth of TWD 1.69 billion. The enterprise value is 1.42 billion.
| Market Cap | 1.69B |
| Enterprise Value | 1.42B |
Important Dates
The last earnings date was Friday, April 18, 2025.
| Earnings Date | Apr 18, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
InnoPharmax has 107.58 million shares outstanding. The number of shares has increased by 5.83% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 107.58M |
| Shares Change (YoY) | +5.83% |
| Shares Change (QoQ) | +5.17% |
| Owned by Insiders (%) | 2.06% |
| Owned by Institutions (%) | 3.41% |
| Float | 89.75M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 52.29 |
| PB Ratio | 2.80 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -14.33 |
| EV / Sales | 44.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -18.54 |
Financial Position
The company has a current ratio of 10.90, with a Debt / Equity ratio of 0.03.
| Current Ratio | 10.90 |
| Quick Ratio | 9.74 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.20 |
| Interest Coverage | -312.64 |
Financial Efficiency
Return on equity (ROE) is -18.41% and return on invested capital (ROIC) is -10.76%.
| Return on Equity (ROE) | -18.41% |
| Return on Assets (ROA) | -10.37% |
| Return on Invested Capital (ROIC) | -10.76% |
| Return on Capital Employed (ROCE) | -15.90% |
| Revenue Per Employee | 949,912 |
| Profits Per Employee | -2.92M |
| Employee Count | 34 |
| Asset Turnover | 0.06 |
| Inventory Turnover | 0.51 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +4.04% in the last 52 weeks. The beta is 0.49, so InnoPharmax's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +4.04% |
| 50-Day Moving Average | 15.14 |
| 200-Day Moving Average | 18.01 |
| Relative Strength Index (RSI) | 53.75 |
| Average Volume (20 Days) | 373,932 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, InnoPharmax had revenue of TWD 32.30 million and -99.29 million in losses. Loss per share was -1.02.
| Revenue | 32.30M |
| Gross Profit | 20.76M |
| Operating Income | -95.98M |
| Pretax Income | -96.97M |
| Net Income | -99.29M |
| EBITDA | -93.92M |
| EBIT | -95.98M |
| Loss Per Share | -1.02 |
Balance Sheet
The company has 281.23 million in cash and 15.39 million in debt, giving a net cash position of 265.84 million or 2.47 per share.
| Cash & Cash Equivalents | 281.23M |
| Total Debt | 15.39M |
| Net Cash | 265.84M |
| Net Cash Per Share | 2.47 |
| Equity (Book Value) | 602.85M |
| Book Value Per Share | 5.60 |
| Working Capital | 290.89M |
Cash Flow
In the last 12 months, operating cash flow was -76.22 million and capital expenditures -527,000, giving a free cash flow of -76.75 million.
| Operating Cash Flow | -76.22M |
| Capital Expenditures | -527,000 |
| Free Cash Flow | -76.75M |
| FCF Per Share | -0.71 |
Margins
| Gross Margin | 64.29% |
| Operating Margin | -297.18% |
| Pretax Margin | -300.23% |
| Profit Margin | n/a |
| EBITDA Margin | -290.81% |
| EBIT Margin | -297.18% |
| FCF Margin | n/a |
Dividends & Yields
InnoPharmax does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.83% |
| Shareholder Yield | -5.83% |
| Earnings Yield | -5.88% |
| FCF Yield | -4.54% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InnoPharmax has an Altman Z-Score of 33.54.
| Altman Z-Score | 33.54 |
| Piotroski F-Score | n/a |